A phase 2 study of intravenous panobinostat in patients with castration-resistant prostate cancer

Cancer Chemotherapy and Pharmacology

Volumn 72, Issue 3, 2013, Pages 537-544

  Rathkopf, Dana E ^a   Picus, Joel ^b   Hussain, Arif ^c   Ellard, Susan ^d   Chi, Kim Nguyen ^d   Nydam, Thomas ^e   Allen Freda, Erin ^e   Mishra, Kaushal Kishor ^e   Porro, Maria Grazia ^e   Scher, Howard I ^a   Wilding, George ^f  

^a MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^b USA   (United States)

^c UNIVERSITY OF MARYLAND   (United States)

^d BRITISH COLUMBIA CANCER AGENCY   (Canada)

^e NOVARTIS PHARMA AG   (Switzerland)

^f UNIVERSITY OF WISCONSIN   (United States)

Author keywords

Deacetylase inhibitor; Panobinostat; Prostate cancer; Prostate specific antigen

Indexed keywords

CARCINOEMBRYONIC ANTIGEN; PANOBINOSTAT; PROSTATE SPECIFIC ANTIGEN;

ADULT; AGED; ANEMIA; ARTHRALGIA; ARTICLE; BACKACHE; CANCER SURVIVAL; CASTRATION RESISTANT PROSTATE CANCER; CLINICAL ARTICLE; CLINICAL EFFECTIVENESS; CONSTIPATION; CREATININE BLOOD LEVEL; DECREASED APPETITE; DEHYDRATION; DIARRHEA; DRUG EFFICACY; DRUG EXPOSURE; DRUG RESPONSE; DRUG SAFETY; DRUG TOLERABILITY; DYSGEUSIA; DYSPNEA; ELECTROCARDIOGRAPHY MONITORING; FATIGUE; FEVER; HUMAN; HYPOCALCEMIA; HYPOKALEMIA; HYPONATREMIA; HYPOPHOSPHATEMIA; HYPOTENSION; LEUKOPENIA; LIMB PAIN; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; MUSCLE WEAKNESS; NAUSEA; PERIPHERAL EDEMA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; QT PROLONGATION; SIDE EFFECT; SOLID TUMOR; ST SEGMENT; THROMBOCYTE COUNT; THROMBOCYTOPENIA; TREATMENT DURATION; TREATMENT OUTCOME; VOMITING; WEIGHT REDUCTION;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; DISEASE-FREE SURVIVAL; HISTONE DEACETYLASE INHIBITORS; HUMANS; HYDROXAMIC ACIDS; INDOLES; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; ORCHIECTOMY; PROSTATE-SPECIFIC ANTIGEN; PROSTATIC NEOPLASMS; TREATMENT OUTCOME;

EID: 84883487383     PISSN: 03445704     EISSN: 14320843     Source Type: Journal    
DOI: 10.1007/s00280-013-2224-8     Document Type: Article

References (33)

1. Albany C, Alva AS, Aparicio AM, Singal R, Yellapragada S, Sonpavde G, Hahn NM (2011) Epigenetics in prostate cancer. Prostate Cancer 2011:580318
2. Patra SK, Patra A, Dahiya R (2001) Histone deacetylase and DNA methyltransferase in human prostate cancer. Biochem Biophys Res Commun 287:705-713
3. Fu M, Rao M, Wang C, Sakamaki T, Wang J, Di Vizio D, Zhang X, Albanese C, Balk S, Chang C, Fan S, Rosen E, Palvimo JJ, Janne OA, Muratoglu S, Avantaggiati ML, Pestell RG (2003) Acetylation of androgen receptor enhances coactivator binding and promotes prostate cancer cell growth. Mol Cell Biol 23:8563-8575
4. Abbas A, Gupta S (2008) The role of histone deacetylases in prostate cancer. Epigenetics 3:300-309
5. Walton TJ, Li G, Seth R, McArdle SE, Bishop MC, Rees RC (2008) DNA demethylation and histone deacetylation inhibition co-operate to re-express estrogen receptor beta and induce apoptosis in prostate cancer cell-lines. Prostate 68:210-222
6. Seligson DB, Horvath S, Shi T, Yu H, Tze S, Grunstein M, Kurdistani SK (2005) Global histone modification patterns predict risk of prostate cancer recurrence. Nature 435:1262-1266
7. Weichert W, Roske A, Gekeler V, Beckers T, Stephan C, Jung K, Fritzsche FR, Niesporek S, Denkert C, Dietel M, Kristiansen G (2008) Histone deacetylases 1, 2 and 3 are highly expressed in prostate cancer and HDAC2 expression is associated with shorter PSA relapse time after radical prostatectomy. Br J Cancer 98:604-610
8. Zhou LX, Li T, Huang YR, Sha JJ, Sun P, Li D (2010) Application of histone modification in the risk prediction of the biochemical recurrence after radical prostatectomy. Asian J Androl 12:171-179
9. Fiskus W, Ren Y, Mohapatra A, Bali P, Mandawat A, Rao R, Herger B, Yang Y, Atadja P, Wu J, Bhalla K (2007) Hydroxamic acid analogue histone deacetylase inhibitors attenuate estrogen receptor-alpha levels and transcriptional activity: a result of hyperacetylation and inhibition of chaperone function of heat shock protein 90. Clin Cancer Res 13:4882-4890
10. Zoubeidi A, Zardan A, Beraldi E, Fazli L, Sowery R, Rennie P, Nelson C, Gleave M (2007) Cooperative interactions between androgen receptor (AR) and heat-shock protein 27 facilitate AR transcriptional activity. Cancer Res 67:10455-10465
11. Trepel J, Mollapour M, Giaccone G, Neckers L (2010) Targeting the dynamic HSP90 complex in cancer. Nat Rev Cancer 10:537-549
12. Butler LM, Agus DB, Scher HI, Higgins B, Rose A, Cordon-Cardo C, Thaler HT, Rifkind RA, Marks PA, Richon VM (2000) Suberoylanilide hydroxamic acid, an inhibitor of histone deacetylase, suppresses the growth of prostate cancer cells in vitro and in vivo. Cancer Res 60:5165-5170
13. Rokhlin OW, Taghiyev AF, Guseva NV, Glover RA, Chumakov PM, Kravchenko JE, Cohen MB (2005) Androgen regulates apoptosis induced by TNFR family ligands via multiple signaling pathways in LNCaP. Oncogene 24:6773-6784
14. Welsbie DS, Xu J, Chen Y, Borsu L, Scher HI, Rosen N, Sawyers CL (2009) Histone deacetylases are required for androgen receptor function in hormone-sensitive and castrate-resistant prostate cancer. Cancer Res 69:958-966
15. Tan J, Zhuang L, Jiang X, Yang KK, Karuturi KM, Yu Q (2006) Apoptosis signal-regulating kinase 1 is a direct target of E2F1 and contributes to histone deacetylase inhibitor-induced apoptosis through positive feedback regulation of E2F1 apoptotic activity. J Biol Chem 281:10508-10515
16. Martinez-Balbas MA, Bauer UM, Nielsen SJ, Brehm A, Kouzarides T (2000) Regulation of E2F1 activity by acetylation. EMBO J 19:662-671
17. Atadja P (2009) Development of the pan-DAC inhibitor panobinostat (LBH589): successes and challenges. Cancer Lett 280:233-241
18. Prince HM, Bishton MJ, Johnstone RW (2009) Panobinostat (LBH589): a potent pan-deacetylase inhibitor with promising activity against hematologic and solid tumors. Future Oncol 5:601-612
19. Liu X, Gomez-Pinillos A, Liu X, Johnson EM, Ferrari AC (2010) Induction of bicalutamide sensitivity in prostate cancer cells by an epigenetic Puralpha-mediated decrease in androgen receptor levels. Prostate 70:179-189
20. Shao W, Growney J, O'Connor G, Feng Y, Scher H, Yao Y, Fawell S, Atadja P (2008) Efficacy of panobinostat (LBH589) in prostate cancer cell models: targeting the androgen receptor in hormone-refractory prostate cancer (HRPC). Genitourinary Cancers Symposium:[abstract 216]
21. Rathkopf D, Wong BY, Ross RW, Anand A, Tanaka E, Woo MM, Hu J, Dzik-Jurasz A, Yang W, Scher HI (2010) A phase I study of oral panobinostat alone and in combination with docetaxel in patients with castration-resistant prostate cancer. Cancer Chemother Pharmacol 66:181-189
22. Scher HI, Halabi S, Tannock I, Morris M, Sternberg CN, Carducci MA, Eisenberger MA, Higano C, Bubley GJ, Dreicer R, Petrylak D, Kantoff P, Basch E, Kelly WK, Figg WD, Small EJ, Beer TM, Wilding G, Martin A, Hussain M, Prostate Cancer Clinical Trials Working Group (2008) Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group. J Clin Oncol 26:1148-1159
23. Scher HI, Morris MJ, Kelly WK, Schwartz LH, Heller G (2005) Prostate cancer clinical trial end points: "RECIST"ing a step backwards. Clin Cancer Res 11:5223-5232
24. Sharma S, Vogelzang NJ, Beck J, Patnaik A, Mita M, Dugan M, Hwang A, Masson E, Culver KW, Prince H (2007) Phase I pharmacokinetic (PK) and pharmacodynamic (PD) study of LBH589, a novel deacetylase (DAC) inhibitor given intravenously on a new once weekly schedule. J Clin Oncol 25:[abstract 14019]
25. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, Gwyther SG (2000) New guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of Canada. J Natl Cancer Inst 92:205-216
26. Bubley GJ, Carducci M, Dahut W, Dawson N, Daliani D, Eisenberger M, Figg WD, Freidlin B, Halabi S, Hudes G, Hussain M, Kaplan R, Myers C, Oh W, Petrylak DP, Reed E, Roth B, Sartor O, Scher H, Simons J, Sinibaldi V, Small EJ, Smith MR, Trump DL, Wilding G (1999) Eligibility and response guidelines for phase II clinical trials in androgen-independent prostate cancer: recommendations from the Prostate-Specific Antigen Working Group. J Clin Oncol 17:3461-3467
27. Beekman KW, Fleming MT, Scher HI, Slovin SF, Ishill NM, Heller G, Kelly WK (2005) Second-line chemotherapy for prostate cancer: patient characteristics and survival. Clin Prostate Cancer 4:86-90
28. Halabi S, Vogelzang NJ, Ou SS, Owzar K, Archer L, Small EJ (2009) Progression-free survival as a predictor of overall survival in men with castrate-resistant prostate cancer. J Clin Oncol 27:2766-2771
29. de Bono JS, Logothetis CJ, Molina A, Fizazi K, North S, Chu L, Chi KN, Jones RJ, Goodman OB Jr, Saad F, Staffurth JN, Mainwaring P, Harland S, Flaig TW, Hutson TE, Cheng T, Patterson H, Hainsworth JD, Ryan CJ, Sternberg CN, Ellard SL, Flechon A, Saleh M, Scholz M, Efstathiou E, Zivi A, Bianchini D, Loriot Y, Chieffo N, Kheoh T, Haqq CM, Scher HI, COU-AA-301 Investigators (2011) Abiraterone and increased survival in metastatic prostate cancer. N Engl J Med 364:1995-2005
30. Scher HI, Fizazi K, Saad F, Taplin ME, Sternberg CN, Miller K, de Wit R, Mulders P, Chi KN, Shore ND, Armstrong AJ, Flaig TW, Flechon A, Mainwaring P, Fleming M, Hainsworth JD, Hirmand M, Selby B, Seely L, de Bono JS, AFFIRM Investigators (2012) Increased survival with enzalutamide in prostate cancer after chemotherapy. N Engl J Med 367:1187-1197
31. Bradley D, Rathkopf D, Dunn R, Stadler WM, Liu G, Smith DC, Pili R, Zwiebel J, Scher H, Hussain M (2009) Vorinostat in advanced prostate cancer patients progressing on prior chemotherapy (National Cancer Institute Trial 6862): trial results and interleukin-6 analysis: a study by the Department of Defense Prostate Cancer Clinical Trial Consortium and University of Chicago Phase 2 Consortium. Cancer 115:5541-5549
32. Schrump DS (2009) Cytotoxicity mediated by histone deacetylase inhibitors in cancer cells: mechanisms and potential clinical implications. Clin Cancer Res 15:3947-3957
33. Subramanian S, Bates S, Wright J, Espinoza-Delgado I, Piekarz R (2010) Clinical toxicities of histone deacetylase inhibitors. Pharmaceuticals 3:2751-2767